abstract |
A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17 beta -estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 mg of drospirenone and 0.1 to 0.2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days. |